CN112316135A - 治疗金黄色葡萄球菌相关疾病的方法 - Google Patents

治疗金黄色葡萄球菌相关疾病的方法 Download PDF

Info

Publication number
CN112316135A
CN112316135A CN202011217117.7A CN202011217117A CN112316135A CN 112316135 A CN112316135 A CN 112316135A CN 202011217117 A CN202011217117 A CN 202011217117A CN 112316135 A CN112316135 A CN 112316135A
Authority
CN
China
Prior art keywords
ser
gly
thr
val
tyr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202011217117.7A
Other languages
English (en)
Chinese (zh)
Inventor
B·塞尔曼
C·特卡奇克
M·汉密尔顿
L·华
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune LLC
Original Assignee
MedImmune LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune LLC filed Critical MedImmune LLC
Publication of CN112316135A publication Critical patent/CN112316135A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202011217117.7A 2012-11-06 2013-11-05 治疗金黄色葡萄球菌相关疾病的方法 Pending CN112316135A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261723128P 2012-11-06 2012-11-06
US61/723,128 2012-11-06
CN201380057604.3A CN104780934A (zh) 2012-11-06 2013-11-05 治疗金黄色葡萄球菌相关疾病的方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201380057604.3A Division CN104780934A (zh) 2012-11-06 2013-11-05 治疗金黄色葡萄球菌相关疾病的方法

Publications (1)

Publication Number Publication Date
CN112316135A true CN112316135A (zh) 2021-02-05

Family

ID=50685101

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202011217117.7A Pending CN112316135A (zh) 2012-11-06 2013-11-05 治疗金黄色葡萄球菌相关疾病的方法
CN201380057604.3A Pending CN104780934A (zh) 2012-11-06 2013-11-05 治疗金黄色葡萄球菌相关疾病的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201380057604.3A Pending CN104780934A (zh) 2012-11-06 2013-11-05 治疗金黄色葡萄球菌相关疾病的方法

Country Status (13)

Country Link
US (3) US9845348B2 (enExample)
EP (1) EP2928490B1 (enExample)
JP (2) JP6506172B2 (enExample)
KR (3) KR20150092738A (enExample)
CN (2) CN112316135A (enExample)
AU (2) AU2013341421A1 (enExample)
BR (1) BR112015010126B1 (enExample)
CA (1) CA2890385C (enExample)
ES (1) ES2912267T3 (enExample)
MX (1) MX367082B (enExample)
RU (1) RU2661406C2 (enExample)
SG (2) SG11201503231YA (enExample)
WO (1) WO2014074470A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114729033A (zh) * 2019-09-20 2022-07-08 迈威(上海)生物科技股份有限公司 抗α-溶血素的抗体及其应用

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2838211C (en) 2011-06-10 2023-08-01 Medimmmune Limited Anti-pseudomonas psl binding molecules and uses thereof
HUE050985T2 (hu) 2011-11-07 2021-01-28 Medimmune Ltd Pseudomonas PSL és PCRV elleni kötõmolekulát alkalmazó kombinációs terápiák
KR20150092738A (ko) * 2012-11-06 2015-08-13 메디뮨 엘엘씨 에스.아우레우스 연관 질병의 치료 방법
CN104968797B (zh) * 2012-11-06 2018-11-30 米迪缪尼有限公司 金黄色葡萄球菌表面决定簇的抗体
TWI719938B (zh) 2014-06-19 2021-03-01 美商麥迪紐有限責任公司 多重細菌感染之治療
TWI781130B (zh) 2017-01-03 2022-10-21 美商再生元醫藥公司 抗金黃色葡萄球菌溶血素ａ毒素之人類抗體
TWI902669B (zh) 2018-07-24 2025-11-01 美商麥迪紐有限責任公司 抗金黃色葡萄球菌凝集因子a(clfa)之抗體
EP3864040A1 (en) 2018-10-09 2021-08-18 Medimmune, LLC Antibodies directed against staphylococcus aureus leukotoxins
WO2020076789A2 (en) 2018-10-09 2020-04-16 Medimmune, Llc Combinations of anti-staphylococcus aureus antibodies
TW202100549A (zh) 2019-03-13 2021-01-01 美商麥迪紐有限責任公司 降低金黃色葡萄球菌在定殖的患者中之感染

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009029831A1 (en) * 2007-08-31 2009-03-05 University Of Chicago Methods and compositions related to immunizing against staphylococcal lung diseases and conditions
US20120201892A1 (en) * 2009-07-16 2012-08-09 Savannah River Nuclear Solutions, Llc Porous-wall hollow glass microspheres as carriers for biomolecules
WO2012109285A2 (en) * 2011-02-08 2012-08-16 Medimmune, Llc Antibodies that specifically bind staphylococcus aureus alpha toxin and methods of use
WO2012109167A1 (en) * 2011-02-08 2012-08-16 Integrated Biotherapeutics, Inc. Immunogenic composition comprising alpha-hemolysin oligopeptides

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2719397A1 (en) * 2006-06-12 2014-04-16 GlaxoSmithKline Biologicals SA Use of alpha-toxin for treating and preventing staphylococcus infections
EP2284193A1 (en) * 2009-08-10 2011-02-16 Kenta Biotech AG Human monoclonal antibody against S. aureus derived apha-toxin and its use in treating or preventing abscess formation
KR20150092738A (ko) * 2012-11-06 2015-08-13 메디뮨 엘엘씨 에스.아우레우스 연관 질병의 치료 방법
CN104968797B (zh) 2012-11-06 2018-11-30 米迪缪尼有限公司 金黄色葡萄球菌表面决定簇的抗体
TWI719938B (zh) 2014-06-19 2021-03-01 美商麥迪紐有限責任公司 多重細菌感染之治療
WO2017075188A2 (en) 2015-10-30 2017-05-04 Medimmune, Llc Methods of using anti-alpha toxin antibody

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009029831A1 (en) * 2007-08-31 2009-03-05 University Of Chicago Methods and compositions related to immunizing against staphylococcal lung diseases and conditions
US20120201892A1 (en) * 2009-07-16 2012-08-09 Savannah River Nuclear Solutions, Llc Porous-wall hollow glass microspheres as carriers for biomolecules
WO2012109285A2 (en) * 2011-02-08 2012-08-16 Medimmune, Llc Antibodies that specifically bind staphylococcus aureus alpha toxin and methods of use
WO2012109167A1 (en) * 2011-02-08 2012-08-16 Integrated Biotherapeutics, Inc. Immunogenic composition comprising alpha-hemolysin oligopeptides

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114729033A (zh) * 2019-09-20 2022-07-08 迈威(上海)生物科技股份有限公司 抗α-溶血素的抗体及其应用

Also Published As

Publication number Publication date
KR20210083389A (ko) 2021-07-06
US20200109191A1 (en) 2020-04-09
JP6926138B2 (ja) 2021-08-25
JP2019142888A (ja) 2019-08-29
BR112015010126A2 (enExample) 2017-08-22
RU2661406C2 (ru) 2018-07-16
US20190002540A1 (en) 2019-01-03
JP6506172B2 (ja) 2019-04-24
JP2015536951A (ja) 2015-12-24
SG10201703677VA (en) 2017-06-29
MX367082B (es) 2019-08-05
EP2928490A1 (en) 2015-10-14
EP2928490B1 (en) 2022-03-30
HK1215173A1 (zh) 2016-08-19
AU2018236849B2 (en) 2020-05-21
KR20200102533A (ko) 2020-08-31
US10457724B2 (en) 2019-10-29
MX2015005481A (es) 2016-01-14
AU2018236849A1 (en) 2018-10-18
KR102272744B1 (ko) 2021-07-06
CA2890385A1 (en) 2014-05-15
EP2928490A4 (en) 2016-11-02
CN104780934A (zh) 2015-07-15
BR112015010126B1 (pt) 2022-11-01
SG11201503231YA (en) 2015-05-28
WO2014074470A1 (en) 2014-05-15
ES2912267T3 (es) 2022-05-25
US9845348B2 (en) 2017-12-19
KR20150092738A (ko) 2015-08-13
US20160257733A1 (en) 2016-09-08
CA2890385C (en) 2022-07-12
US10759849B2 (en) 2020-09-01
AU2013341421A1 (en) 2015-06-04
RU2015121617A (ru) 2016-12-27

Similar Documents

Publication Publication Date Title
US10759849B2 (en) Methods of treating S. aureus-associated diseases
KR102288394B1 (ko) 스타필로코커스 아우레우스 표면 결정인자에 대한 항체
KR101993839B1 (ko) 스타필로코커스 아우레우스 알파 독소에 특이적으로 결합하는 항체 및 이의 사용 방법
BR112014011028B1 (pt) anticorpo biespecífico, composição, e, uso da composição
US20150044168A1 (en) Treatment of Multiple Sclerosis With Anti-CD19 Antibody
KR20210072057A (ko) 항-황색포도상구균 항체의 조합
WO2022159744A1 (en) Treatment of chronic prurigo
HK1215173B (en) Methods of treating s. aureus-associated diseases
TW202506180A (zh) 用於癌症治療之pd-1/tigit結合蛋白
RU2808018C2 (ru) Антитела к поверхностным детерминантам s. aureus
TW202511292A (zh) 用於治療ＮＳＣＬＣ及ｃＨＬ之ＰＤ－１／ＴＩＭ－３結合蛋白
CN119654169A (zh) 抗体-药物缀合物和双特异性检查点抑制剂的组合
CN117120089A (zh) 慢性痒疹的治疗
HK40025295A (en) Antibodies to s. aureus surface determinants

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination